乳腺增生病药物治疗机制研究进展

乳腺增生病（Hyperplastic disease of breast， HDB）是我国育龄女性最常见的乳腺疾病，且发病率呈逐年上升趋势。青春期至绝经期间均可发病，且近年来发病年龄呈低龄化，其恶变率随年龄增长而逐渐增加。HDB与乳腺癌有共同的危险因素，癌变危险性较正常人高，尤其是乳腺不典型增生已被公认为乳腺癌的癌前病变，所以HDB的危害不容小觑。现代医学、传统医学及二者结合治疗HDB的各种方案中，药物治疗都起着至关重要的作用，不同药物作用机制不同，甚至有些药物作用机制尚不明确。综述目前治疗HDB的药物及其具体作用机制，并探讨其优缺点，为进一步探索研发出新的抗HDB药物提供较为全面及科学的参考。

Advances in research on drug treatment mechanism of breast hyperplasia

Hyperplastic disease of breast (HDB) is the most common breast disease in women of childbearing age in China, and the incidence rate is increasing year by year. It can occur from puberty to menopause, and the age of onset is younger in recent years, and its malignant rate gradually increases with age. HDB and breast cancer have common risk factors, and the risk of cancer is higher than that of normal people. Especially breast atypical hyperplasia has been recognized as a precancerous lesion of breast cancer, so the harm of HDB should not be underestimated. Modern medicine, traditional medicine and the combination of the two in the treatment of HDB, drug treatment play a vital role, the mechanism of action of different drugs is different, and even some mechanisms of action of drugs are not clear. This article reviews the current treatment of HDB drugs and its specific mechanism of action, and explores its advantages and disadvantages, providing a more comprehensive and scientific reference for further exploration and development of new anti-HDB drugs.